US Bancorp DE Lowers Position in Kenvue Inc. $KVUE

US Bancorp DE cut its stake in shares of Kenvue Inc. (NYSE:KVUE) by 10.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 322,735 shares of the company’s stock after selling 36,862 shares during the period. US Bancorp DE’s holdings in Kenvue were worth $6,755,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Evergreen Wealth Solutions LLC lifted its position in shares of Kenvue by 2.6% in the first quarter. Evergreen Wealth Solutions LLC now owns 16,769 shares of the company’s stock valued at $402,000 after acquiring an additional 432 shares in the last quarter. Scott & Selber Inc. lifted its position in shares of Kenvue by 0.4% in the first quarter. Scott & Selber Inc. now owns 106,621 shares of the company’s stock valued at $2,557,000 after acquiring an additional 475 shares in the last quarter. Wealth Alliance LLC lifted its position in shares of Kenvue by 1.6% in the first quarter. Wealth Alliance LLC now owns 31,778 shares of the company’s stock valued at $762,000 after acquiring an additional 486 shares in the last quarter. Everett Harris & Co. CA lifted its position in shares of Kenvue by 1.4% in the first quarter. Everett Harris & Co. CA now owns 36,971 shares of the company’s stock valued at $887,000 after acquiring an additional 500 shares in the last quarter. Finally, Proffitt & Goodson Inc. lifted its position in shares of Kenvue by 8.2% in the second quarter. Proffitt & Goodson Inc. now owns 6,831 shares of the company’s stock valued at $143,000 after acquiring an additional 517 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Trading Down 1.0%

Shares of KVUE stock opened at $16.68 on Monday. The stock’s 50-day moving average price is $19.15 and its 200-day moving average price is $21.31. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12-month low of $15.47 and a 12-month high of $25.17. The stock has a market capitalization of $32.00 billion, a price-to-earnings ratio of 22.53, a price-to-earnings-growth ratio of 2.39 and a beta of 0.72.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The company had revenue of $3.84 billion for the quarter, compared to analysts’ expectations of $3.94 billion. During the same period in the previous year, the firm posted $0.32 earnings per share. The firm’s revenue for the quarter was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities research analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were paid a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, August 13th. This is an increase from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.83 annualized dividend and a yield of 5.0%. Kenvue’s payout ratio is presently 112.16%.

Analyst Upgrades and Downgrades

KVUE has been the topic of several research analyst reports. Evercore ISI lowered their price objective on Kenvue from $23.00 to $18.00 and set an “in-line” rating on the stock in a research report on Tuesday, September 23rd. Canaccord Genuity Group lowered their price objective on Kenvue from $29.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. JPMorgan Chase & Co. reduced their target price on Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a report on Friday. Royal Bank Of Canada reduced their target price on Kenvue from $24.00 to $22.00 and set a “sector perform” rating on the stock in a report on Friday, August 8th. Finally, The Goldman Sachs Group reduced their target price on Kenvue from $22.00 to $19.00 and set a “neutral” rating on the stock in a report on Thursday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Kenvue has a consensus rating of “Hold” and an average price target of $21.18.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.